Table 2.

Overview of genetically modified alloCAR T cell therapies for hematologic and solid tumors.

CAR T variant	Target antigen	Cancer type	Engineering strategy	Ref.
Multiplex CRISPR-edited alloCAR T	CD19	B-cell leukemia/lymphoma	CRISPR multiplexing; TRAC, B2M, and PD-1 locus deletion	72
CRISPR-engineered alloCAR T	CD19	Pediatric BCP-ALL	Donor-derived, second-generation CAR; retroviral and lentiviral constructs with 4.1BB signaling	74
Multiplex CRISPR-edited alloCAR T	CD19/CD22	R/R B-ALL	CRISPR multiplexing; TRAC and CD52 locus deletion	75
tKOc alloCAR T	CD19	B-cell malignancies	HLA class I, II, and TCR triple knockout via Cas9/sgRNA ribonucleoprotein electroporation	76
Hypoimmune alloCAR T	CD19	B-cell malignanciesa	CRISPR-Cas9-edited HIP T cells; B2M, CIITA, TRAC locus disruption; CD47 and anti-CD19 CAR via lentiviral transduction	78
SB transposon-engineered alloCAR T	CD19	Lymphoid malignanciesa	Non-viral sleeping beauty transposons for CD19-28z.CAR transduction and CRISPR-based TCR inactivation	79
ALLO-715	BCMA	R/R multiple myeloma	Allogeneic anti-BCMA CAR	80
UCART19	CD19	Pediatric/adult B-ALL molecular remission	TALEN-based allogeneic CAR19 T; TCR α chain and CD52 locus deletion	81,82
Base-edited CAR7 T	CD7	T-ALL	Base editing to generate universal CAR T; CD7 inactivation; TCRβ chain inactivation	83

BCP-ALL, B-cell precursor acute lymphoblastic leukemia; R/R B-ALL, relapsed/refractory B-cell acute lymphoblastic leukemia; T-ALL, T-cell acute lymphoblastic leukemia.

^aUsing humanized mouse models.